New European Tool Helps Capture the Full Experience of Cancer Survivorship

woman speaking to a therapist

As more people survive cancer and live for many years after treatment, understanding life beyond diagnosis has become an increasingly important healthcare priority. 

Researchers from the European Organisation for Research and Treatment of Cancer (EORTC) have now validated the EORTC QLQ-SURV100, a new questionnaire designed specifically to assess the health-related quality of life of cancer survivors.

The international study published in the European Journal of Cancer in Sept 2026 involved a large and diverse population of cancer survivors across multiple countries and confirmed that the questionnaire provides a reliable and valid way of measuring the physical, mental and social dimensions of survivorship. Available in 21 languages, the tool was shown to work consistently across different cancer types, healthcare settings and cultural contexts.

What makes the QLQ-SURV100 distinctive is its broad focus on the realities of life after cancer. In addition to physical symptoms and late effects of treatment, it examines issues such as emotional wellbeing, social relationships, employment, daily functioning, personal growth, and wider social determinants of health.

The questionnaire was also able to distinguish between groups of survivors with different experiences, including variations in treatment intensity, age, sex and the presence of other health conditions. This suggests it can help identify where additional support may be needed and provide a more personalised understanding of survivorship challenges.

Importantly, researchers believe the tool could support emerging models of survivorship care across Europe, including nurse-led follow-up services, integrated primary and specialist care, supported self-management programmes, and long-term survivorship clinics. Early experience from a Danish late-effects clinic suggests it may also have practical value in routine care by helping clinicians identify areas where survivors are struggling and guiding more tailored interventions.

Although the questionnaire contains 100 items, participants completed it in an average of eight minutes, demonstrating that meaningful assessment of survivorship can be both comprehensive and feasible in real-world settings.

Why this matters

This study reflects a broader shift in European cancer policy and research. Success is no longer measured solely by survival rates but also by how well people live after cancer. Quality of life, mental wellbeing, social participation, employment, and long-term support are increasingly recognised as essential outcomes of cancer care.

Key takeaway

As more people survive cancer, Europe is shifting attention toward supporting long-term wellbeing, not just treatment success.

The validated QLQ-SURV100 gives researchers and healthcare professionals a powerful new tool to understand the lived experience of cancer survivors, helping ensure that survivorship care focuses not only on extending life, but also on supporting wellbeing, participation and quality of life after treatment.

Source: International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100, European Journal of Cancer (2026). https://www.ejcancer.com/article/S0959-8049(2600740-9/fulltext).

Related Articles